The Best Psychedelic for Depression? Psilocybin vs Ketamine vs LSD vs Ayahuasca

If you have been reading about psychedelic-assisted therapy for depression, you have probably noticed that every compound is described as promising. That framing is not wrong, but it flattens some very real differences. Psilocybin, ketamine, LSD, and ayahuasca do not work the same way, do not carry the same evidence, and are not equally available to you today. Identifying the best psychedelic for depression in your particular case means looking at four things at once: what the research actually supports, what you can legally access, what your current medications allow, and what kind of experience you are prepared to have. What follows is a comparison, not a recommendation.

Why Comparing Psychedelics for Depression Is Harder Than It Looks

Most published comparisons stack effect sizes side by side as if the trials were interchangeable. They are not. A study of 29 people in Brazil and a Phase 3 program with several hundred participants are not the same kind of evidence, even if both report a reduction on the same depression rating scale. Three factors distort naive comparisons:

• Trial size and stage. Phase 3 evidence is the standard regulators use. Small open-label studies are hypothesis-generating, not conclusive.
• Population. Treatment-resistant depression (people who have failed at least two adequate antidepressant trials) is a harder population than general major depressive disorder. A compound tested in the harder population and still showing benefit is telling you something different.
• Blinding. Psychedelics are notoriously difficult to blind. Participants usually know whether they received an active dose, which inflates expectancy effects on both sides of the trial.

Psilocybin for Depression: The Strongest Late-Stage Evidence

Psilocybin currently has the deepest clinical evidence base of any classic psychedelic for depression. Compass Pathways ran two Phase 3 trials of COMP360, a synthetic pharmaceutical-grade psilocybin, in treatment-resistant depression. The first trial found that a single 25mg dose produced a statistically significant and clinically meaningful reduction in symptom severity compared with placebo at six weeks. The second trial, comparing fixed doses, reached its primary endpoint as well. No unexpected safety findings emerged, and there was no meaningful imbalance in suicidal ideation between the treatment and placebo groups.

That is the first time a classic psychedelic has produced consistent Phase 3 results in psychiatry. Phase 3 is where most promising compounds fail.

The dosing question deserves plain language. A 25mg dose of synthetic psilocybin is roughly equivalent to 3 to 4 grams of dried Psilocybe cubensis. That equivalence is approximate, because psilocybin content varies considerably by strain, by specimen, and by how the mushrooms were dried and stored. Golden Teacher and B+ sit in the moderate range, Mazatapec is generally described as gentler, Albino A+ tends toward moderate-high, and Penis Envy carries substantially more psilocybin than most strains. Weight alone is an unreliable proxy for dose without a known source, which is one reason clinical trials use synthetic psilocybin rather than mushrooms.

Outside of trials, people encounter psilocybin in dried whole mushrooms, in tea (often steeped with ginger to reduce nausea), as lemon tek (dried mushrooms soaked in citrus juice before ingestion, which is thought to speed onset), in capsules for more consistent dosing, and increasingly in chocolates and edibles where dose consistency is genuinely unpredictable.

Where psilocybin fits: people with treatment-resistant depression who can access a legal regulated program (Oregon and Colorado) or a clinical trial, who can commit to a five to six hour session with preparation and integration, and who are not on medications that create interaction risk.

Ketamine for Depression: The Fastest and Most Accessible Option

Ketamine occupies a strange position in this comparison. It is not a classic psychedelic, it works through a different receptor system (NMDA rather than serotonin 2A), and it is the only option on this list that is legally available to most Americans right now. Its defining characteristic is speed. Where SSRIs take four to six weeks to show effect, ketamine frequently produces measurable improvement within hours to days. For someone in acute crisis, that difference is not academic.

The tradeoff is durability. A single ketamine session typically produces effects lasting days to a couple of weeks, which is why clinical protocols usually involve a series of six sessions over two to three weeks, followed by maintenance. Psilocybin’s promise, by contrast, is that one or two sessions may hold for months. Ketamine gets you relief faster; psilocybin may hold it longer. That is the core clinical tension between them, and we have written more on how psilocybin and ketamine compare across mechanism, setting, and legality.

Ketamine also comes in several forms with meaningfully different profiles. IV infusion is the most studied and most controlled. Intranasal esketamine (Spravato) is FDA-approved for treatment-resistant depression and requires monitored administration. Oral and sublingual troches, often prescribed through telehealth, are the least studied and carry the least oversight. Preparation still matters for ketamine, even though it is often presented as a purely medical procedure.

Where ketamine fits: people who need relief soon, people who cannot legally or practically reach psilocybin, and people who want to work within a conventional medical framework. It is the only realistic option for most of the country, including states like Pennsylvania, where psilocybin remains illegal.

LSD for Depression: Real Programs, Results Still Pending

LSD is further along than most people assume and less proven than the enthusiasm suggests. MindMed’s MM120, a pharmaceutically optimized form of LSD delivered as an orally disintegrating tablet, has moved into Phase 3. Its Phase 2b results in generalized anxiety disorder were published in JAMA and showed a clear dose-response relationship, with the 100 microgram dose selected for Phase 3.

For depression specifically, the relevant study is Emerge, a Phase 3 trial of MM120 in major depressive disorder measuring change in depression scores at week six. Topline results are expected in the second half of 2026. In other words, the depression data does not exist yet.

What can be said now is that LSD’s anxiety results were strong enough to justify a full Phase 3 program, and that anxiety and depression overlap substantially in both symptoms and populations. That is a reasonable basis for interest, not for a treatment decision. Our coverage of the landmark LSD anxiety trial goes into what that study actually found. The practical obstacle is duration: an LSD session runs eight to twelve hours, a full day of clinical supervision, which is part of why the compound has lagged behind psilocybin commercially despite comparable pharmacology.

Where LSD fits: for now, clinical trial participants only. Anyone telling you LSD is an established depression treatment in 2026 is ahead of the evidence.

Ayahuasca for Depression: One Good Trial, Serious Caveats

Ayahuasca has the thinnest formal evidence base of the four and the most complicated risk profile. The anchor study is a 2019 randomized placebo-controlled trial published in Psychological Medicine involving 29 patients with treatment-resistant depression. Participants received either a single dose of ayahuasca or placebo, and the ayahuasca group showed significantly greater reductions in depression scores. The researchers themselves noted an unusually high placebo response, which they attributed partly to the supportive environment and partly to the high rate of comorbid personality disorders in the sample. It should be read for what it is: a small, single, honest study. Twenty-nine people is not a Phase 3 program.

The risk picture is where ayahuasca separates sharply from the others. The brew contains MAO inhibitors, which interact dangerously with SSRIs, SNRIs, and a long list of other medications and foods. This is not a theoretical concern. Serotonin syndrome is the specific risk, and it can be fatal. Anyone on an antidepressant considering ayahuasca needs medical supervision for a taper, not a retreat brochure. Our guide to what to know before an ayahuasca experience covers this in detail, as does our overview of who should pause before pursuing psychedelic therapy at all.

There is also no regulated ayahuasca pathway in the United States outside of specific religious exemptions. In practice, pursuing ayahuasca means traveling to a retreat in a jurisdiction where oversight ranges from rigorous to nonexistent.

Where ayahuasca fits: people drawn to the ceremonial dimension of the work, who are medication-free or properly tapered under supervision, and who have done serious diligence on the specific retreat and facilitators.

So Which Psychedelic Is Actually Right for Depression?

Here is the honest framing. The compound is the least important variable in your decision. What determines the shape of your options is a shorter list:

• Your medications. If you are on an SSRI, this is the first conversation, not the last. Interaction risk varies enormously across these four compounds, and ayahuasca is in a category of its own. Talking to your physician is a prerequisite, not an optional step.
• Your diagnosis. Treatment-resistant depression, major depressive disorder, and depression with a significant trauma component are not the same clinical problem and do not point to the same medicine.
• Your legal reality. In most of the United States, ketamine is the only lawful option. That single fact resolves the question for a great many people before any evidence comparison begins.
• Your capacity. A ketamine infusion takes about an hour. A psilocybin session takes most of a day. An ayahuasca retreat takes a week and a flight.
• Your history. A personal or family history of psychosis or mania, current lithium use, and certain cardiac conditions are firm stops, not negotiable preferences.

The pattern we see repeatedly is that people arrive having chosen a compound and then work backward to justify it. The more useful sequence is the reverse: start with your constraints, and let them narrow the field. Our broader overview of what the 2026 research shows on psychedelics for depression is a reasonable next read.

The Decision You Are Actually Making

Choosing among psychedelics for depression is less like choosing a drug and more like choosing a path. Each of these four comes bundled with a setting, a duration, a legal status, a level of oversight, and a set of people who will or will not be with you when it gets difficult. The medicine matters. The container matters more. A well-supported ketamine protocol with a clinician who prepares you properly will do more for you than an unsupported psilocybin experience in a jurisdiction where you have no recourse if something goes wrong.